Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version
SECTIONS
- Executive Summary
- Introduction
- Penetrance of Inherited Susceptibility to Hereditary Breast and/or Gynecologic Cancers
- Multigene (Panel) Testing
- High-Penetrance Breast and/or Gynecologic Cancer Susceptibility Genes
- Moderate-Penetrance Genes Associated With Breast and/or Gynecologic Cancer
- Low-Penetrance Genes and Loci
- Clinical Management ofBRCA Mutation Carriers
- Clinical Management of Other Hereditary Breast and/or Gynecologic Cancer Syndromes
- Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes
- Changes to This Summary (06/24/2016)
- About This PDQ Summary
- View All Sections
Changes to This Summary (06/24/2016)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that an unselected cohort of 810 women of Mexican ancestry with breast cancer were tested; 4.3% had a BRCA mutation. Eight of the 35 mutations identified were the BRCA1 exon 9–12 deletion (cited Torres-Mejía as reference 72).
Updated National Comprehensive Cancer Network as reference 89.
Updated National Comprehensive Cancer Network as reference 33.
Added Menes et al. as reference 254.
Revised text to state that the risk of contralateral breast cancer (CBC) was 1.8-fold higher in those with a first-degree relative with breast cancer in the Women's Environmental Cancer and Radiation Epidemiology Study (WECARE) study. Also added text about a study of 810 women with stage I or stage II breast cancer who had a BRCA1 orBRCA2 mutation identified in the family; in this cohort, 149 developed CBC; the 15-year actuarial risk was 36.1% among BRCA1 mutation carriers and 28.5% among BRCA2 mutation carriers. Risks were higher among those diagnosed before age 50 years, and the risk of CBC varied by family history among women whose initial breast cancer was diagnosed before age 50 years (cited Metcalfe et al. as reference 305).
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario